Wells Fargo’s Clarus Therapeutics Holdings, Inc. Common Stock CRXT Stock Holding History

Wells Fargo’s Portfolio CRXT Stock Details CRXT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-230	Closed	–	–	7884
2022 Q2	$0	Buy	230 +190	+475%	+$133	﹤0.01%	7953
2022 Q1	$0	Buy	40 +15	+60%	+$19	﹤0.01%	8276
2021 Q4	$0	Buy	+25	New	+$109	﹤0.01%	8186

Other funds holding CRXT

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Wells Fargo's CRXT Position: Q3 2022 in Review

Wells Fargo sold out of Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) in Q3 2022, closing a stake of 230 shares.

Wells Fargo first reported a position in CRXT in Q4 2021 and held it in 3 quarters. The position peaked at $0 in Q2 2022. 2 funds tracked by Wall St. Rank hold CRXT as of Q3 2022.

Wells Fargo reported no remaining Clarus Therapeutics Holdings, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Wells Fargo sold 230 Clarus Therapeutics Holdings, Inc. Common Stock shares in Q3 2022.
Wells Fargo first reported a position in Clarus Therapeutics Holdings, Inc. Common Stock in Q4 2021 and held it in 3 quarters.
Wells Fargo's Clarus Therapeutics Holdings, Inc. Common Stock position peaked at $0 in Q2 2022.
2 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Common Stock as of Q3 2022.

Based on Wells Fargo's 13F filing for Q3 2022, filed 14 Nov 2022.